All In Biotech

Drug Trial Radar · NCT01042379

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 5,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

5,000

Planned (sponsor's estimate)

Start

Mar 1, 2010

Primary completion

Dec 2030

Study completion Dec 2031

Sponsor

Lead sponsor
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 5, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.

Conditions

  • Breast Neoplasms
  • Breast Cancer
  • Breast Tumors
  • Angiosarcoma
  • TNBC - Triple-Negative Breast Cancer
  • HER2-positive Breast Cancer
  • HER2-negative Breast Cancer
  • Hormone Receptor Positive Tumor
  • Hormone Receptor Negative Tumor
  • Early-stage Breast Cancer
  • Locally Advanced Breast Cancer

Interventions

  • Standard TherapyDrug

    Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16

  • AMG 386 with or without TrastuzumabDrug

    Arm is closed.

  • AMG 479 (Ganitumab) plus MetforminDrug

    Arm is closed.

  • MK-2206 with or without TrastuzumabDrug

    Arm is closed.

  • AMG 386 and TrastuzumabDrug

    Arm is closed.

  • T-DM1 and PertuzumabDrug

    Arm is closed.

  • Pertuzumab and TrastuzumabDrug

    Arm is closed for Accrual. Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization

  • GanetespibDrug

    Arm is closed.

  • ABT-888Drug

    Arm is closed.

  • NeratinibDrug

    Arm is closed.

  • PLX3397Drug

    Arm is closed.

  • Pembrolizumab - 4 cycleDrug

    Arm is closed.

  • Talazoparib plus IrinotecanDrug

    Arm is closed.

  • Patritumab and TrastuzumabDrug

    Arm is closed.

  • Pembrolizumab - 8 cycleDrug

    Arm is closed.

  • SGN-LIV1ADrug

    Arm is closed. SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16

  • Durvalumab plus OlaparibDrug

    Arm is closed.

  • SD-101 + PembrolizumabDrug

    Arm is closed. SD-101: IT injection 2 mg/ml (1 ml for T2 tumors, 2 ml for \>T3 tumors) weekly x 4, then every 3 weeks x 2 cycles 1,2,3,4,7,10 Pembrolizumab: 200mg IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles

  • Tucatinib plus trastuzumab and pertuzumabDrug

    Arm is closed. Tucatinib: 300 mg PO BID 12 weeks CLOSED Tucatinib: 250 mg PO BID 12 weeks CLOSED Tucatinib adaptive: 150mg BID days 1-28, 250mg BID days 29-84 Trastuzumab: 4 mg/kg IV (loading dose) cycle 1; 2 mg/kg (thereafter) cycles 2-12 Pertuzumab: 840 mg IV (loading dose) cycle 1; 420 mg (thereafter) cycles 4, 7 and 10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles

  • CemiplimabDrug

    Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles

  • Cemiplimab plus REGN3767Drug

    Arm is closed. Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 REGN 3767: 1600 mg q3W X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles

  • Trilaciclib with or without trastuzumab + pertuzumabDrug

    Arm closed for accrual. Trilaciclib: 240 mg/m2 IV weekly cycle 1-16 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles For HER2+: Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization

  • SYD985 ([vic-]trastuzumab duocarmazine)Drug

    Arm is closed. SYD985: 1.2 mg/kg IV (q3w x 12 weeks) cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles

  • Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumabDrug

    Arm is closed. For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle

  • Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumabDrug

    Arm is closed. For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle

  • AmcenestrantDrug

    Arm is closed. Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks.

  • Amcenestrant + AbemaciclibDrug

    Arm is closed. Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Abemaciclib (Verzenio), 150mg BID, p.o., for 24 weeks

  • Amcenestrant + LetrozoleDrug

    Arm is closed. Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Letrozole (Femara), 2.5mg QD, p.o., for 24 weeks

  • ARX788Drug

    Arm is closed. ARX788, 1.5 mg/kg Q3W, IV for 12 weeks

  • ARX788 + CemiplimabDrug

    Arm is closed. ARX788, 1.5 mg/kg Q3W, IV for 12 weeks Cemiplimab, 350 mg Q3W, IV for 12 weeks

  • VV1 + CemiplimabDrug

    Arm is closed. VV1, 3x10\^9 TCID50 once (day-8), Intra-tumoral injection Cemiplimab, 350 mg Q3W, IV for 12 weeks

  • Datopotamab deruxtecanDrug

    Arm is closed. Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks

  • Datopotamab deruxtecan + DurvalumabDrug

    Arm is closed. Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks Durvalumab, 1120 mg Q3W, IV for 12 weeks

  • ZanidatamabDrug

    Zanidatamab: IV Infusion at a 2-tiered flat dose. 1,800mg (\<70 kg) and 2400mg (≥70 kg). Neoadjuvant doing of zanidatamab: The initial dose will be administered on Cycle 1 Day 1, with Cycle 2 Day 1 occurring 14 days thereafter, followed by subsequent dosing every 3 weeks (Q3W) for a total of up to 5 doses in block A, up to 4 doses Block B, up to 5 doses Block C. Adjuvant dosing of zanidatamab: Administered every 3 weeks (Q3W) for a total of 1 year of HER2 based therapy. The total number of adjuvant weeks will be dependent on the number of weeks of exposure of zanidatamab in Blocks A, B, and C.

  • LasofoxifeneDrug

    Arm is closed. Lasofoxifene: 5.0 mg QD, p.o., for 24 weeks

  • Z-endoxifenDrug

    Arm is closed. Z-endoxifen: 10 mg QD, p.o., for 24 weeks

  • ARV-471Drug

    Arm is closed. ARV-471: 200 mg QD, p.o, for 24 weeks.

  • ARV-471 + LetrozoleDrug

    Arm is closed. ARV-471: 200 mg QD, p.o, for 24 weeks Letrozole: 2.5 mg QD, p.o, for 24 weeks

  • ARV-471 + AbemaciclibDrug

    Arm is closed. ARV-471: 200 mg QD, p.o, for 24 weeks Abemaciclib: 150 mg BID, p.o, for 24 weeks

  • Endoxifen + AbemaciclibDrug

    Z-endoxifen: 80 mg QD, p.o., for 24 weeks Abemaciclib: 150 mg BID, p.o, for 20 weeks

  • Rilvegostomig + TDXdDrug

    Arm closed to accrual Rilvegostomig: 750mg IV Q3W for 12 weeks TDXd: 5.4 mg/kg IV Q3W for 12 weeks

  • Dan222 + NiraparibDrug

    Arm is closed. DAN222: 8mg/m2 IV QW for 12 weeks Niraparib: 200mg QD p.p., 12 weeks

  • Sarilumab + Cemiplimab + PaclitaxelDrug

    Arm is closed to accrual. Sarilumab: 200mg Subcutaneous injection Q2W for 12 weeks Cemiplimab: 350mg IV Q3W for 12 weeks Paclitaxel: 80 mg/m2 IV QW for 12 weeks

  • GSK 5733584Drug

    Arm is open for accrual. Route: Intravenous infusion Dosage Form: 4.8 mg/kg intravenous Q3W for injection. Will receive a max of 12 weeks.

  • GSK 5733584 + DostarlimabDrug

    Arm is open for accrual. GSK 5733584 Route: Intravenous Infusion Dosage Form: 4.8 mg/kg intravenous Q3W for injection x 12 weeks max. Dostarlimab Route: Intravenous Infusion Dosage Form: 500 mg fixed dose intravenous Q3W for infusion x 12 weeks max.

  • Ivonescimab (20mg/kg Q3W)Drug

    Strengths to be used in trial: 1. 20 mg/kg IV Q3W monotherapy 2. 20 mg/kg IV Q3W with paclitaxel 3. 20 mg/kg IV Q3W with carboplatin and paclitaxel. Standard Regimen: 20 mg/kg IV Q3W. Patients in Block A will receive a minimum of 6 weeks a maximum of 12 weeks of Ivonescimab monotherapy in Block A. Patients that have completed Block A, may receive ivonescimab plus paclitaxel or ivonescimab plus paclitaxel plus carboplatin in Block B (depending on subtype).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry.Time frame: Post surgery based on upto 36-week treatment

Locations

42 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Mayo Clinic - Scottsdale

    Scottsdale, Arizona · Not yet recruiting

  • University of Arizona

    Tucson, Arizona · Active not recruiting

  • University of California - Davis, Comprehensive Cancer Center

    Davis, California · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • University of California San Diego

    La Jolla, California · Recruiting

  • University of Southern California

    Los Angeles, California · Recruiting

  • HOAG Memorial Hospital Presbyterian

    Newport Beach, California · Recruiting

  • University of California San Francisco (UCSF)

    San Francisco, California · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Georgetown University Medical Center

    Washington D.C., District of Columbia · Recruiting

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • Loyola University

    Maywood, Illinois · Recruiting

  • University of Kansas

    Westwood, Kansas · Active not recruiting

  • Herbert-Herman Cancer Center, Sparrow Hospital

    Lansing, Michigan · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center

    Saint Louis Park, Minnesota · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York · Recruiting

  • Laura and Isaac Perlmutter Cancer Center / NYU Langone Health

    New York, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • University of Rochester Wilmot Cancer Institute

    Rochester, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Wake Forest Baptist Comprehensive Cancer Center

    Winston-Salem, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • The Ohio State University, Stefanie Spielman Comprehensive Breast Center

    Columbus, Ohio · Recruiting

  • Oregon Health & Science Institute (OHSU)

    Portland, Oregon · Recruiting

  • University of Pennsylvania (U Penn)

    Philadelphia, Pennsylvania · Recruiting

  • University Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Active not recruiting

  • Sanford Clinical Research

    Sioux Falls, South Dakota · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Active not recruiting

  • University of Texas, Southwestern Medical Center

    Dallas, Texas · Active not recruiting

  • University of Texas, M.D. Anderson Cancer Center

    Houston, Texas · Active not recruiting

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah · Recruiting

  • Inova Health System

    Falls Church, Virginia · Active not recruiting

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.